Harriet Rothschild

Ms. Harriet Rothschild

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2017 in Science
Verified
Journal Article
Closed access
PDF file
NCNicholas G. Crawford
Nicholas G. Crawford
DKDerek E. Kelly
Derek E. Kelly
MHMatthew E. B. Hansen
Matthew E. B. Hansen
Marcia Holsbach BeltrameMarcia Holsbach Beltrame
Marcia Holsbach Beltrame
SFShaohua Fan
Shaohua Fan
STSarah A. Tishkoff
Sarah A. Tishkoff
African genomics and skin color: Skin color varies among human populations and is thought to be under selection, with light skin maximizing vitamin D production at higher latitudes and dark skin providing UV protection in equatorial zones. To identify the genes that give rise to the palette of human skin tones, Crawford et al. applied genome-wide analyses across diverse African populations (see the Perspective by Tang and Barsh). Genetic variants were identified with likely function in skin phenotypes. Comparison to model organisms verified a conserved function of MFSD12 in pigmentation. A global genetic panel was used to trace how alleles associated with skin color likely moved across the globe as humans migrated, both within and out of Africa. Science , this issue p. eaan8433 ; see also p. 867

30 November 2018 in Science
Verified
Journal Article
Closed access
PDF file
JAJulien Ablain
Julien Ablain
MXMengshu Xu
Mengshu Xu
HRHarriet Rothschild
Harriet Rothschild
RJRichard C. Jordan
Richard C. Jordan
JMJeffrey K. Mito
Jeffrey K. Mito
IYIwei Yeh
Iwei Yeh
Hunting and fishing for cancer genes: Mucosal melanoma is a rare, but deadly, form of melanoma that occurs in sun-protected tissues. Little is known about the genetic alterations that drive the growth of these tumors. Ablain et al. sequenced mucosal melanomas from 43 patients and found that a substantial fraction showed inactivation or loss of SPRED1 , a gene that encodes a negative regulator of RAS–MAPK (mitogen-activated protein kinase) signaling. Using a platform called MAZERATI (Modeling Approach in Zebrafish for Rapid Tumor Initiation), they discovered that SPRED1 loss may help explain the poor response of melanoma patients to drugs that inhibit the KIT tyrosine kinase. The results suggest that a combination of KIT inhibitors and drugs that inhibit MAPK signaling may be more effective. Science , this issue p. 1055

1 June 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
JCJiyeon Choi
Jiyeon Choi
TZTongwu Zhang
Tongwu Zhang
AVAndrew Vu
Andrew Vu
JAJulien Ablain
Julien Ablain
MMMatthew M. Makowski
Matthew M. Makowski
KBKevin M. Brown
Kevin M. Brown
Genome-wide association studies (GWAS) have identified ~20 melanoma susceptibility loci, most of which are not functionally characterized. Here we report an approach integrating massively-parallel reporter assays (MPRA) with cell-type-specific epigenome and expression quantitative trait loci (eQTL) to identify susceptibility genes/variants from multiple GWAS loci. From 832 high-LD variants, we identify 39 candidate functional variants from 14 loci displaying allelic transcriptional activity, a subset of which corroborates four colocalizing melanocytecis-eQTL genes. Among these, we further characterize the locus encompassing the HIV-1 restriction gene,MX2(Chr21q22.3), and validate a functional intronic variant, rs398206. rs398206 mediates the binding of the transcription factor, YY1, to increaseMX2levels, consistent with thecis-eQTL ofMX2in primary human melanocytes. Melanocyte-specific expression of humanMX2in a zebrafish model demonstrates accelerated melanoma formation in aBRAFV600Ebackground. Our integrative approach streamlines GWAS follow-up studies and highlights a pleiotropic function ofMX2in melanoma susceptibility.

5 April 2023 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
HRHarriet Rothschild
Harriet Rothschild
ECElle Clelland
Elle Clelland
APAnne Patterson
Anne Patterson
JMJulissa Molina-Vega
Julissa Molina-Vega
MKMandeep Kaur
Mandeep Kaur
RMRita A. Mukhtar
Rita A. Mukhtar
Purpose: HER2 overexpression has a central role in breast cancer carcinogenesis and is associated with poor prognosis if untreated. Lately, identification of HER2-low breast cancer has been proposed to select patients for novel HER2-directed chemotherapy and includes cancers with immunohistochemistry 1 + or 2 + with negative FISH, encompassing approximately 55–60% of all breast carcinomas. In early-stage breast cancer, the prognostic significance of HER2 low-disease is less well understood, with a particular paucity of data evaluating the prevalence and implications of HER2-low status in invasive lobular carcinoma (ILC). Methods: We evaluated 666 stage I-III ILC tumors from a prospectively maintained institutional database, comparing clinicopathologic features and disease-free survival (DFS) using a multivariable Cox proportional hazards model. Results: HER2-low status was common in this cohort of patients with ILC, but most clinicopathologic features did not differ between HER2-low and HER2-negative cases. However, when adjusting for tumor size, number of positive nodes, ER/PR status, and local therapy received, patients with HER2-low status had worse disease-free survival (DFS) than those with HER2-negative tumors (hazard ratio 2.0, 95% confidence interval 1.0–4.1, p = 0.05). Conclusion: This difference in DFS supports the notion that HER2-low and HER2-negative early stage ILC may differ clinically, despite similar clinicopathologic features. Further investigation into the potential benefit of HER2 targeted therapy in HER2-low early-stage breast cancer, and specifically lobular cancer, is warranted to ensure optimal outcomes in this distinct tumor subtype.

13 October 2022 in Nature Genetics
Verified
Journal Article
Open access
PDF file
JAJulien Ablain
Julien Ablain
AMAmira Al Mahi
Amira Al Mahi
HRHarriet Rothschild
Harriet Rothschild
MPMeera Prasad
Meera Prasad
SASophie Aires
Sophie Aires
LZLeonard I. Zon
Leonard I. Zon
Cancer genetics has uncovered many tumor-suppressor and oncogenic pathways, but few alterations have revealed mechanisms involved in tumor spreading. Here, we examined the role of the third most significant chromosomal deletion in human melanoma that inactivates the adherens junction gene NECTIN1 in 55% of cases. We found that NECTIN1 loss stimulates melanoma cell migration in vitro and spreading in vivo in both zebrafish and human tumors specifically in response to decreased IGF1 signaling. In human melanoma biopsy specimens, adherens junctions were seen exclusively in areas with low IGF1 levels, but not in NECTIN1-deficient tumors. Our study establishes NECTIN1 as a major determinant of melanoma dissemination and uncovers a genetic control of the response to microenvironmental signals.

25 May 2021 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
AGAlexa C. Glencer
Alexa C. Glencer
JWJasmine M. Wong
Jasmine M. Wong
NHNola Hylton
Nola Hylton
GKGregor Krings
Gregor Krings
EMEmma McCune
Emma McCune
MCMichael J. Campbell
Michael J. Campbell
Ductal carcinoma in situ (DCIS) is a risk factor for the subsequent development of invasive breast cancer. High-risk features include age 5 cm, high-grade, palpable mass, hormone receptor negativity, and HER2 positivity. We have previously shown that immune infiltrates are positively associated with these high-risk features, suggesting that manipulating the immune microenvironment in high-risk DCIS could potentially alter disease progression. Patients with high-risk DCIS were enrolled in this 3 × 3 phase 1 dose-escalation pilot study of 2, 4, and 8 mg intralesional injections of the PD-1 immune checkpoint inhibitor, pembrolizumab. Study participants received two intralesional injections, three weeks apart, prior to surgery. Tissue from pre-treatment biopsies and post-treatment surgical resections was analyzed using multiplex immunofluorescence (mIF) staining for various immune cell populations. The intralesional injections were easily administered and well-tolerated. mIF analyses demonstrated significant increases in total T cell and CD8+ T cell percentages in most patients after receiving pembrolizumab, even at the 2 mg dose. T cell expansion was confined primarily to the stroma rather than within DCIS-containing ducts. Neither cleaved caspase 3 (CC3) staining, a marker for apoptosis, nor DCIS volume (as measured by MRI) changed significantly following treatment. Intralesional injection of pembrolizumab is safe and feasible in patients with DCIS. Nearly all patients experienced robust total and CD8+ T cell responses. However, we did not observe evidence of cell death or tumor volume decrease by MRI, suggesting that additional strategies may be needed to elicit stronger anti-tumor immunity.